BiolineRX schizophrenia treatment trial in India approved

BiolineRX CEO: We look forward to announcing top-line results from the CLARITY trial in early 2013.

Drug development company BiolineRX Ltd. (TASE:BLRX) announced that it has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020. This molecule is a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia. In June 2011, BioLineRx announced the commencement of patient enrollment in the CLARITY trial in Romania, which is currently ongoing according to schedule.

Bioline said that the initiation visits at the first few Indian clinical research centers will be completed this month, with enrollment of the first patient expected in December. Other centers in India will also be joining the trial over the coming weeks. Overall, the trial is expected to be conducted at 18 sites in India, 14 sites in Romania and four sites in Israel.

Bioline CEO Dr. Kinneret Savitsky said, "The approval to commence the trial in India represents an important milestone in the progress of the BL-1020 CLARITY trial. In addition, we are also intending to submit in the near future a regulatory package to the authorities in Israel in order to open four Israeli sites for our clinical trial. The trial, if successful, will support BL-1020's unique potential as an antipsychotic therapy that also improves cognition."

She added, "We look forward to announcing top-line results from the CLARITY trial in early 2013. Also, concurrent with the progress of the trial and in accordance with our business strategy, we have renewed our efforts to seek an out-licensing partner to continue development and commercialization of BL-1020.”

The CLARITY trial is a randomized, double-blinded, positive-controlled study that will enroll up to 450 patients experiencing an acute exacerbation of schizophrenia. The goal of the study is to determine the short-term and long-term cognitive efficacy as well as the anti-psychotic efficacy, safety and tolerability of BL-1020 in schizophrenia patients, over periods of six, 12 and 24 weeks.

Published by Globes, Israel business news - - on November 23, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018